ArticleJournal of the Endocrine Society2022
Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
Article in Journal of the Endocrine Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study.Acta dermato-venereologica · 2024Trial
- Article
- Thyroid Function, Inflammation, and HDL-Cholesterol in Women with Acne: A Real-World Cross-Sectional Study Integrating Biochemistry and Thyroid Ultrasound.Journal of clinical medicine · 2026Article
- Comprehensive analysis of proteomics and lactylation proteomics in ovarian granulosa cells of patients with polycystic ovary syndrome.Clinical proteomics · 2026Article
- PRACT-India: Practical Recommendations on Acne Care and Medical Treatment in India-A Modified Delphi Consensus.Antibiotics (Basel, Switzerland) · 2025Article
- Multifactorial Refractory Acne in Women: Insights from a Case Series Involving Hormonal-, Metabolic-, and Corticosteroid-Related Triggers.Life (Basel, Switzerland) · 2025Article
- Cardiovascular disease risk prediction by Framingham risk score in women with polycystic ovary syndrome.Reproductive biology and endocrinology : RB&E · 2025Article
- The clinical predictors of biochemical hyperandrogenemia and its relation to treatment resistance in women with acne.Postepy dermatologii i alergologii · 2025Article
- Assessing Anti-Acne PotentialsCurrent drug targets · 2025Review
- Clinical Characteristics and Manifestations of Polycystic Ovary Syndrome: a Comparative Study.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2025Article
- Deciphering the Role of Androgen in the Dermatologic Manifestations of Polycystic Ovary Syndrome Patients: A State-of-the-Art Review.Diagnostics (Basel, Switzerland) · 2024Review
- Does Prevalence of Female Sexual Dysfunction Differ among Infertile Patients with or without Polycystic Ovary Syndrome: A Cross-Sectional Study.International journal of fertility & sterility · 2024Article
- Characterizing clinical and hormonal profiles of acne in north African women with polycystic ovary syndrome.Archives of dermatological research · 2024Article
- Androgen Deprivation Therapy and the Risk of Newly Developed Dry Eye Syndrome in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in the Republic of Korea.Journal of clinical medicine · 2024Article
- Prevalence and Clinical Management of Adrenal Tumour-Related Hyperandrogenism: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- A Review of the Risk Factors Associated with Endometrial Hyperplasia During Perimenopause.International journal of women's health · 2024Review
- Case report: A pregnant woman accidental treated with spironolactone in mid-gestation.Frontiers in pharmacology · 2024Article
- Prevalence of and Risk Factors Associated with Polycystic Ovary Syndrome Among Female University Students of Health Sciences in a Middle Eastern Country.Women's health reports (New Rochelle, N.Y.) · 2024Article
- Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs.Journal of clinical medicine · 2023Article
- Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial.Frontiers in pharmacology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 8 institutions in 5 countries.
Funding
Abstract
In endocrine and reproductive endocrine literature, adult female acne is considered as a possible clinical expression of hyperandrogenism, with most polycystic ovary syndrome (PCOS) guidelines considering acne as a condition of androgen excess. Adult female acne, however, in the dermatological literature is considered as an inflammatory skin disease and new guidelines on adult female acne have been produced by dermatological societies, with little perspective from any endocrine or reproductive endocrine points of view. An expert task force was appointed by the AE-PCOS society to determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female adult acne. The following are the recommendations (level of evidence A or B): (1) diagnosis of female adult acne is mainly clinical, but a grading tool is needed for optimizing the treatment; (2) measurement of serum androgen values (total testosterone, free testosterone, and dehydroepiandrosterone sulfate) by high-quality assays is recommended in all women with adult acne; (3) in women with adult acne and proven hyperandrogenism, oral combined estroprogestins should be added to the topical or systemic treatment of acne, independently of severity of acne; (4) all second- and third-generation estroprogestins may be used, independently of the estrogen dose and progestin component; (5) spironolactone may be added to estroprogestins in women with moderate or severe hyperandrogenic adult acne, not responding to usual treatments; (6) estroprogestins may be used in nonhyperandrogenic patients with adult acne as second-line therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.